MolMed will provide GSK with vectors for the oncology field
MILAN, Italy I July 13, 2018 I MolMed S.p.A. (MLMD.MI), medical biotechnology company focusing on research, development, manufacturing, and clinical validation of Cell & Gene therapies to treat cancer and rare diseases, today announces the signing of a three-year Agreement, with GSK, science-led global healthcare company, for the development and manufacturing of lentiviral vectors to be used for clinical application in GSK’s oncology programme.
Riccardo Palmisano, MolMed CEO, commented: “Following the long lasting collaboration between MolMed and GSK and the recent transfer of our development and manufacturing agreement in the field of rare diseases from GSK to Orchard Therapeutics, we are now delighted to announce this new collaboration in the oncology field with our historical partner GSK. This agreement represents a real milestone for our GMP manufacturing services business pillar and it confirms our strategic decision to invest in the new GMP facility located in Bresso, supporting the continuous growth of our third party revenues. At the same time, the trust of a leading global healthcare company furtherly confirms our leadership as a major player in cell & gene field”.
About MolMed
MolMed S.p.A. is a biotechnology company focused on research, development, manufacturing and clinical validation of innovative anticancer therapies. MolMed’s product portfolio includes proprietary anti-tumor therapies in clinical and preclinical development: Zalmoxis® (TK) is a cell therapy based on donor T cells genetically engineered to enable bone marrow transplants from partially compatible donors for patients with high-risk hematological malignancies, eliminating post-transplant immunosuppression prophylaxis and inducing a rapid immune reconstitution. Zalmoxis® received Orphan Drug Designation and is currently in Phase III in a high-risk population of acute leukemia patients, but has already obtained a Conditional Marketing Authorization by the European Commission in the second half of 2016 as well as reimbursement conditions in Italy at the end of 2017 and in Germany at the beginning of 2018. Still focusing on this cell & gene technology, the company is developing a therapy based on Chimeric Antigen Receptor (CAR), specifically the CAR-T CD44v6, an immune gene therapy project, currently in advanced preclinical development, potentially effective for hematological malignancies and several solid epithelial tumors. MolMed is also the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies for its proprietary products (Zalmoxis®) as well as for third parties and/or in partnership (Strimvelis, a GSK gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. In the framework of innovative anticancer therapies, MolMed’s pipeline also includes NGR-hTNF, a therapeutic agent for solid tumors investigated in a broad clinical program, involving more than 1,000 treated patients. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso.
SOURCE: MolMed
Post Views: 215
MolMed will provide GSK with vectors for the oncology field
MILAN, Italy I July 13, 2018 I MolMed S.p.A. (MLMD.MI), medical biotechnology company focusing on research, development, manufacturing, and clinical validation of Cell & Gene therapies to treat cancer and rare diseases, today announces the signing of a three-year Agreement, with GSK, science-led global healthcare company, for the development and manufacturing of lentiviral vectors to be used for clinical application in GSK’s oncology programme.
Riccardo Palmisano, MolMed CEO, commented: “Following the long lasting collaboration between MolMed and GSK and the recent transfer of our development and manufacturing agreement in the field of rare diseases from GSK to Orchard Therapeutics, we are now delighted to announce this new collaboration in the oncology field with our historical partner GSK. This agreement represents a real milestone for our GMP manufacturing services business pillar and it confirms our strategic decision to invest in the new GMP facility located in Bresso, supporting the continuous growth of our third party revenues. At the same time, the trust of a leading global healthcare company furtherly confirms our leadership as a major player in cell & gene field”.
About MolMed
MolMed S.p.A. is a biotechnology company focused on research, development, manufacturing and clinical validation of innovative anticancer therapies. MolMed’s product portfolio includes proprietary anti-tumor therapies in clinical and preclinical development: Zalmoxis® (TK) is a cell therapy based on donor T cells genetically engineered to enable bone marrow transplants from partially compatible donors for patients with high-risk hematological malignancies, eliminating post-transplant immunosuppression prophylaxis and inducing a rapid immune reconstitution. Zalmoxis® received Orphan Drug Designation and is currently in Phase III in a high-risk population of acute leukemia patients, but has already obtained a Conditional Marketing Authorization by the European Commission in the second half of 2016 as well as reimbursement conditions in Italy at the end of 2017 and in Germany at the beginning of 2018. Still focusing on this cell & gene technology, the company is developing a therapy based on Chimeric Antigen Receptor (CAR), specifically the CAR-T CD44v6, an immune gene therapy project, currently in advanced preclinical development, potentially effective for hematological malignancies and several solid epithelial tumors. MolMed is also the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies for its proprietary products (Zalmoxis®) as well as for third parties and/or in partnership (Strimvelis, a GSK gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. In the framework of innovative anticancer therapies, MolMed’s pipeline also includes NGR-hTNF, a therapeutic agent for solid tumors investigated in a broad clinical program, involving more than 1,000 treated patients. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso.
SOURCE: MolMed
Post Views: 215
